Overcoming the "Antigen Sink" and Hematological Toxicity
One of the most significant hurdles in CD47 development has been the "Antigen Sink" effect. Because CD47 is expressed on healthy red blood cells (RBCs) and platelets, early-generation antibodies often bound to these healthy cells first, causing widespread anemia and thrombocytopenia.
In 2026, "Second-Generation" CD47 therapeutics have solved this through structural engineering:
Affinity Optimization: Newer antibodies, such as IMC-002, are designed with optimized binding affinities that favor the dense CD47 clusters found on tumor cells over the sparse distribution on RBCs.
Fc-Region Engineering: Many 2026 therapeutics utilize "silenced" or "inactive" Fc regions. This ensures that while the antibody blocks the CD47 signal, it doesn't accidentally trigger the immune system to destroy the healthy RBCs it is bound to.
Priming Doses: Clinicians now use a "priming and maintenance" dosing schedule. A small initial dose clears out older, vulnerable RBCs and stimulates the production of young RBCs (reticulocytes) that are more resistant to phagocytosis, followed by higher therapeutic doses to target the tumor.